While the chatter surrounding Biogen’s controversial Alzheimer’s med Aduhelm has largely been centered on a pivotal Medicare reimbursement decision as of late, analysts are pointing to one new study that suggests there may be “room for surprises” when it comes to the treatment’s safety. [Read more…] about Study: Fewer than 1% of geriatric patients with cognitive complaints met Aduhelm research trial criteria. What can we expect about its real-world safety?
Brain activity changes seen after chemo (Reuters):
“For some women with breast cancer, changes in brain activity while multitasking could explain “chemo brain” – reduced mental functioning that many experience after chemotherapy, Belgian researchers say. “Cognitive complaints of people increase with chemotherapy and [Read more…] about Finally, growing awareness of chemotherapy-induced cognitive deficits